This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramírez, J. C.
Right arrow Articles by Esteban, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramírez, J. C.
Right arrow Articles by Esteban, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH

 Previous Article  |  Next Article 

Journal of Virology, August 2000, p. 7651-7655, Vol. 74, No. 16
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector

Juan C. Ramírez, M. Magdalena Gherardi,dagger Dolores Rodríguez, and Mariano Esteban*

Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Campus Universidad Autónoma, E-28049 Madrid, Spain

Received 13 March 2000/Accepted 12 May 2000

A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that after a booster with attenuated recombinant modified vaccinia virus Ankara (rMVA), higher humoral and cellular immune responses to foreign antigens (human immunodeficiency virus type 1 Env and beta -galactosidase) were found in mice preimmunized with rMVA than in mice primed with the virulent Western Reserve strain and boosted with rMVA. This enhancement correlated with higher levels of expression of foreign antigens after the booster.

* Corresponding author. Mailing address: Centro Nacional Biotecnologia (CSIC), Campus Cantoblanco, 28049 Madrid, Spain. Phone: 34-91-585-4503. Fax: 34-91-585-4506. E-mail: mesteban{at}cnb.uam.es.

dagger Present address: Department of Applied Microbiology, Centro de Estudios Farmacológicos y Botánicos (CEFYBO-CONICET), Buenos Aires, Argentina.

Journal of Virology, August 2000, p. 7651-7655, Vol. 74, No. 16
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Mayrhofer, J., Coulibaly, S., Hessel, A., Holzer, G. W., Schwendinger, M., Bruhl, P., Gerencer, M., Crowe, B. A., Shuo, S., Hong, W., Tan, Y. J., Dietrich, B., Sabarth, N., Savidis-Dacho, H., Kistner, O., Barrett, P. N., Falkner, F. G. (2009). Nonreplicating Vaccinia Virus Vectors Expressing the H5 Influenza Virus Hemagglutinin Produced in Modified Vero Cells Induce Robust Protection. J. Virol. 83: 5192-5203 [Abstract] [Full Text]  
  • Stober, C. B., Lange, U. G., Roberts, M. T. M., Alcami, A., Blackwell, J. M. (2007). Heterologous Priming-Boosting with DNA and Modified Vaccinia Virus Ankara Expressing Tryparedoxin Peroxidase Promotes Long-Term Memory against Leishmania major in Susceptible BALB/c Mice. Infect. Immun. 75: 852-860 [Abstract] [Full Text]  
  • Walther, M., Thompson, F. M., Dunachie, S., Keating, S., Todryk, S., Berthoud, T., Andrews, L., Andersen, R. F., Moore, A., Gilbert, S. C., Poulton, I., Dubovsky, F., Tierney, E., Correa, S., Huntcooke, A., Butcher, G., Williams, J., Sinden, R. E., Hill, A. V. S. (2006). Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein.. Infect. Immun. 74: 2706-2716 [Abstract] [Full Text]  
  • Palena, C., Foon, K. A., Panicali, D., Yafal, A. G., Chinsangaram, J., Hodge, J. W., Schlom, J., Tsang, K. Y. (2005). Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood 106: 3515-3523 [Abstract] [Full Text]  
  • Wang, Z., La Rosa, C., Mekhoubad, S., Lacey, S. F., Villacres, M. C., Markel, S., Longmate, J., Ellenhorn, J. D. I., Siliciano, R. F., Buck, C., Britt, W. J., Diamond, D. J. (2004). Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104: 847-856 [Abstract] [Full Text]  
  • Gherardi, M. M., Perez-Jimenez, E., Najera, J. L., Esteban, M. (2004). Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: Enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule. J. Immunol. 172: 6209-6220 [Abstract] [Full Text]  
  • Wang, Z., La Rosa, C., Maas, R., Ly, H., Brewer, J., Mekhoubad, S., Daftarian, P., Longmate, J., Britt, W. J., Diamond, D. J. (2004). Recombinant Modified Vaccinia Virus Ankara Expressing a Soluble Form of Glycoprotein B Causes Durable Immunity and Neutralizing Antibodies against Multiple Strains of Human Cytomegalovirus. J. Virol. 78: 3965-3976 [Abstract] [Full Text]  
  • Cosma, A., Buhler, S., Nagaraj, R., Staib, C., Hammarin, A.-L., Wahren, B., Goebel, F. D., Erfle, V., Sutter, G. (2004). Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia Virus. CVI 11: 406-410 [Abstract] [Full Text]  
  • Hodge, J. W., Poole, D. J., Aarts, W. M., Gomez Yafal, A., Gritz, L., Schlom, J. (2003). Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses. Cancer Res. 63: 7942-7949 [Abstract] [Full Text]  
  • Hornemann, S., Harlin, O., Staib, C., Kisling, S., Erfle, V., Kaspers, B., Hacker, G., Sutter, G. (2003). Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L. J. Virol. 77: 8394-8407 [Abstract] [Full Text]  
  • Gherardi, M. M., Najera, J. L., Perez-Jimenez, E., Guerra, S., Garcia-Sastre, A., Esteban, M. (2003). Prime-Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes. J. Virol. 77: 7048-7057 [Abstract] [Full Text]  
  • Espenschied, J., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., Ellenhorn, J. D. I. (2003). CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model. J. Immunol. 170: 3401-3407 [Abstract] [Full Text]  
  • Harrington, L. E., Most, R. v. d., Whitton, J. L., Ahmed, R. (2002). Recombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope. J. Virol. 76: 3329-3337 [Abstract] [Full Text]  
  • Sharpe, S., Polyanskaya, N., Dennis, M., Sutter, G., Hanke, T., Erfle, V., Hirsch, V., Cranage, M. (2001). Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82: 2215-2223 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»